Clinical Trials Browser

OTHER × Ovarian Neoplasms × liposomal doxorubicin × Clear all

NCT01970722 2026-03-05

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

Phase 1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2 Active not recruiting

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06023862 2025-06-15

DOVE

Phase 2 Recruiting

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT06292286 2025-06-11

SCENIC

Phase NA Recruiting

Ovarian Neoplasms

NCT00170573 2024-12-16

Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

Phase 2 Completed

77 enrolled 9 charts

Ovarian Neoplasms

NCT02312245 2024-12-05

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

13 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03596281 2024-10-18

PEMBOV

Phase 1 Completed

Ovarian Neoplasms

NCT03598270 2024-08-30

ANITA

Phase 3 Completed

Ovarian Neoplasms

NCT01705158 2023-09-06

MYCA

Phase 1/2 Completed

Ovarian Neoplasms

NCT05976932 2023-08-04

Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer

Ovarian Neoplasms

NCT00326456 2023-03-27

MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer

Phase 3 Unknown

Ovarian Neoplasms

NCT01802749 2023-03-24

MITO16MANGO2b

Phase 3 Unknown

Ovarian Neoplasms

NCT02431559 2022-10-10

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

Phase 1/2 Completed

53 enrolled 22 charts

Ovarian Neoplasms

NCT02865811 2022-09-13

Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer

Phase 2 Completed

26 enrolled 19 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01485874 2022-02-15

Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer

Phase 1 Terminated

Ovarian Neoplasms

NCT01379989 2022-02-09

INOVATYON

Phase 3 Completed

Ovarian Neoplasms

NCT01035658 2021-10-28

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

Phase 1/2 Terminated

22 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04679064 2021-08-27

NItCHE-MITO33

Phase 3 Unknown

Ovarian Neoplasms

NCT02903004 2021-08-25

MITO23

Phase 3 Completed

Ovarian Neoplasms

NCT00846612 2019-09-30

Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

Phase 1 Completed

Ovarian Neoplasms, Recurrence

NCT03562533 2019-02-28

Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer

Ovarian Neoplasms

NCT03367182 2019-01-11

REBECA

Ovarian Neoplasms

NCT03539328 2018-05-29

MITO27

Phase 2 Unknown

Ovarian Neoplasms

NCT00720096 2018-01-02

Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan

Phase NA Terminated

4 enrolled 8 charts

Ovarian Neoplasms

NCT03335241 2017-11-13

Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer

Phase 2 Unknown

Ovarian Neoplasms

NCT01637532 2016-01-26

PITCH

Phase 1/2 Completed

Ovarian Neoplasms

NCT00758732 2015-09-28

Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma

Phase 2 Terminated

Neoplasms, Ovarian Neoplasms

NCT00945139 2015-07-31

Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)

Phase 2 Completed

46 enrolled 11 charts

Ovarian Neoplasms

NCT00312650 2015-01-12

Doxil and Gemcitabine in Recurrent Ovarian Cancer

Phase 2 Terminated

Ovarian Neoplasms, Recurrence

NCT01202890 2014-01-08

Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

Phase 1 Terminated

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01388621 2013-08-20

PROVE

Phase 2 Unknown

Ovarian Neoplasms, Recurrence

NCT00861120 2012-10-26

PaLiDo

Phase 2 Completed

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00653328 2012-05-23

Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma

Phase 2 Terminated

15 enrolled 10 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00237627 2012-05-18

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

Phase 1/2 Completed

BreastDermatologicGynecologicLymphoidOther hematologic neoplasmPlasma cell

Congenital Abnormalities, Carcinoma, Ovarian Epithelial, Blast Crisis, Breast Neoplasms, Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Leukemia, Hairy Cell, Leukemia, Mast-Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Ovarian Neoplasms, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Breast Neoplasms, Male, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Intraocular Lymphoma